Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer

Gastrointestinal Cancer

First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study

J Clin Oncol

Lenz HJ, Van Cutsem E, Luisa Limon M, Wong KYM, Hendlisz A, Aglietta M, García-Alfonso P, Neyns B, Luppi G, Cardin DB, Dragovich T, Shah U, Abdullaev S, Gricar J, Ledeine JM, Overman MJ, Lonardi S

doi: 10.1200/JCO.21.01015

Gastrointestinal Cancer

Evaluation of Emergent Mutations in Circulating Cell-Free DNA and Clinical Outcomes in Patients With Metastatic Colorectal Cancer Treated With Panitumumab in the ASPECCT Study

doi: 10.1158/1078-0432.CCR-18-2072.

COMMENTED

Inflammatory Bowel Disease

Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study

doi: 10.1186/s40425-018-0461-4.

Gastrointestinal Cancer

Does Primary Tumor Side Matter in Patients with Metastatic Colon Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy?

Ann Surg Oncol.

Kelly KJ, Alsayadnasser M, Vaida F, Veerapong J, Baumgartner JM, Patel S, Ahmad S, Barone R, Lowy AM

doi: 10.1245/s10434-019-07255-5.

Gastrointestinal Cancer

Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)

doi: 10.1016/j.ejca.2018.10.001.

Gastrointestinal Cancer

Clinical and molecular characterization of early-onset colorectal cancer

Cancer.

Willauer AN, Liu Y, Pereira AAL, Lam M, Morris JS, Raghav KPS, Morris VK, Menter D, Broaddus R, Meric-Bernstam F, Hayes-Jordan A, Huh W, Overman MJ, Kopetz S, Loree JM

doi: 10.1002/cncr.31994.

Gastrointestinal Cancer

Hepatotoxicity from Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation

Hepatology.

Peeraphatdit TB, Wang J, Odenwald MA, Hu S, Hart J, Charlton MR

doi: 10.1002/hep.31227.

Pancreas Diseases

Targeting dual signalling pathways in concert with immune checkpoints for the treatment of pancreatic cancer

Gut.

Knudsen ES, Kumarasamy V, Chung S, Ruiz A, Vail P, Tzetzo S, Wu J, Nambiar R, Seshadri M, Abrams SI, Wang J, Witkiewicz AK

doi: 10.1136/gutjnl-2020-321000.

Gastrointestinal Cancer

Peripheral Circulating Tumor DNA Detection Predicts Poor Outcomes After Liver Resection for Metastatic Colorectal Cancer

Ann Surg Oncol.

Narayan RR, Goldman DA, Gonen M, Reichel J, Huberman KH, Raj S, Viale A, Kemeny NE, Allen PJ, Balachandran VP, D'Angelica MI, DeMatteo RP, Drebin JA, Jarnagin WR, Kingham TP

doi: 10.1245/s10434-

Related content

First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study

Evaluation of Emergent Mutations in Circulating Cell-Free DNA and Clinical Outcomes in Patients With Metastatic Colorectal Cancer Treated With Panitumumab in the ASPECCT Study

Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study

Does Primary Tumor Side Matter in Patients with Metastatic Colon Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy?

Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)

Clinical and molecular characterization of early-onset colorectal cancer

Hepatotoxicity from Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation

Targeting dual signalling pathways in concert with immune checkpoints for the treatment of pancreatic cancer

Peripheral Circulating Tumor DNA Detection Predicts Poor Outcomes After Liver Resection for Metastatic Colorectal Cancer